Where Tech Meets Bio | BiopharmaTrend | Substack

Weekly Tech+Bio #89: Can Robots Bring Drug-Discovery Chemistry Back to the US?

ALSO: Pfizer puts an AI scientist on its R&D data; Formation Bio raises a $600M fund to rescue stranded drugs; Hugging Face releases an open model you…

Nov 4 • Andrii Buvailo, PhD and BiopharmaTrend

Weekly Tech+Bio #88: Big Pharma Is Buying Supercomputers. Where Are the Results?

ALSO: Anthropic’s IPO and pharma, AstraZeneca’s $40M upfront for insitro's Virtual Human; 1,946 OpenAI agents read a mouse brain atlas, and more...

Oct 27 • Andrii Buvailo, PhD and BiopharmaTrend

13 AI Drug Discovery Companies to Watch in 2026

It seems the sentiment has shifted from platform pitches to what there is in the clinical pipeline...

Oct 22 • BiopharmaTrend

Weekly Tech+Bio #87: TechBio 3.0 Is Closing the Loop. Is "Prompt to Drug" Next?

ALSO: ByteDance spins out Anew Labs on a $290M round; Lilly's TuneLab ships a nanobody developability model built on BigHat data; a partial…

Oct 13 • Andrii Buvailo, PhD and BiopharmaTrend

Weekly Tech+Bio #86: OpenAI Backs a Bet on “Rescuing“ Failed Drugs

ALSO: Enveda, Anew Labs and Varda raise over $850M between them; Genentech signs a $1.5B collaboration with Earendil; Neuralink pretrains on 50,000…

Oct 5 • Andrii Buvailo, PhD and BiopharmaTrend

Most Popular

14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools

May 29, 2025 • BiopharmaTrend

The '4th Wave' of AI Drug Discovery is Here, According to This Report

Dec 12, 2024 • Andrii Buvailo, PhD

AI Foundation Models in Biotech: New Paradigm

Oct 1, 2023 • Andrii Buvailo, PhD

'Google Maps' of Human Cells

Nov 26, 2024 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD

Join 11k+ biotech industry professionals tracking strategy signals in the 'techbio' space

Sponsored Features

On Predicting Probability of Technical and Regulatory Success With AI

Insights from The American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Nov 7, 2024 • BiopharmaTrend

Using AI to Predict the Probability of Success in Drug Development

ALSO: Patented AI Platform Identifies Promising Early-Stage Biopharma Assets and Companies

Jun 13, 2024

Building Data Infrastructure for Biology

ALSO: Featuring Omics Solution Providers Market Map, from Multiomics to Spatial Biology

May 23, 2024

A Landscape of AI-discovered Molecules and Target Novelty Analysis

ALSO: Weekly highlights; An AI Model to Predict RNA Expression; How This Company is Building a New Framework for Clinical Trials; Notable Trends and…

Apr 21, 2024

Deep Dives

13 AI Drug Discovery Companies to Watch in 2026

It seems the sentiment has shifted from platform pitches to what there is in the clinical pipeline...

Oct 22 • BiopharmaTrend

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent

Jul 2 • Andrii Buvailo, PhD

My Seven Health Tech Observations From HLTH Europe 2026 Event

AI is moving from writing clinical notes to checking them. "Human-in-the-loop" is becoming a product, not a footnote. Nearly everyone is racing to own…

Jun 26 • Andrii Buvailo, PhD

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO…

Jun 1 • Andrii Buvailo, PhD

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

May 21 • Andrii Buvailo, PhD and Roman Kasianov

Recommendations

Forever.AI: AI, Robotics, Quantum, Longevity, Cryonics & BCI

Alex Zhavoronkov, PhD

The Connected Ideas Project

Alexander Titus

Molecules & Empires

Andrii Buvailo, PhD

Special Competitive Studies Project

SCSP

Recent posts

Weekly Tech+Bio #85: Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

ALSO: Iambic files for a Nasdaq IPO into a rebounding market; Up to $1.4B for desining oral macrocycles with AI; Stanford researchers turn manuscripts…

Sep 23 • Andrii Buvailo, PhD and BiopharmaTrend

Weekly Tech+Bio #84: A Chemist Designed a Drug Candidate with Help of ChatGPT and Gemini

ALSO: Scoring 9 billion DNA variants, agents in drug discovery stack, repurposing for cheap indications, whole-brain connectomics, brain-computer…

Sep 15 • Andrii Buvailo, PhD and BiopharmaTrend

Weekly Tech+Bio #83: The FDA Might Test Clinical AI Like It Tests Doctors

ALSO: Can Claude design proteins? Ageing virtual cells, DNA as a programmable building material, and the tech+bio week in brief.

Aug 26 • Andrii Buvailo, PhD and BiopharmaTrend

Weekly Tech+Bio #82: Industry Vets Grade AI's Progress; Frontier AI Labs Enter CRO Industry; The Rise of In Vivo CAR-T, and More...

Also: IMPORTANT UPDATE ABOUT OUR NEWSLETTER

Aug 18 • Andrii Buvailo, PhD and BiopharmaTrend

The latest from

Andrii Buvailo, PhD

Weekly Tech+Bio #89: Can Robots Bring Drug-Discovery Chemistry Back to the US?

BiopharmaTrend

Weekly Tech+Bio #89: Can Robots Bring Drug-Discovery Chemistry Back to the US?

Roman Kasianov

Is “Rescuing Failed Drugs with AI” a Category Now?

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts